Search Results - Arvind Kinhikar
- Showing 1 - 1 results of 1
-
1
Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial by Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni
Published 2021Call Number: Loading…Connect to this object online.
Located: Loading…
Book